Tanja Obradovic, Therapeutic Strategy Lead of Oncology at Novotech, Senior Advisor of Oncology Drug Development at HopeAI, shared a post on LinkedIn:
“After dust settled – ASCO2026 and what are shifts in development strategy and business focus?
Highlighting 3 major trends supporting translation of science across clinical development to the bedside as a major theme of ASCO this year:
- Precision oncology should guide from start to end
- From the business and development perspective do not hold all your eggs in one geographical basket
- During clinical development plan for frequent interactions with regulators
Recognition of absolutely global impact and service to oncology community at ASCO2026 with outstanding opportunity to meet my colleagues during very impressive exchange we had at Yvonne Awards OncoDaily reception. Positive leaders recognized across many categories of oncology research and many others attending will boldly embrace ‘translational’ challenges of the future we talked about at this American Society of Clinical Oncology (ASCO) meeting.”
Other articles featuring Tanja Obradovic on OncoDaily.